Table 2.

Clinical, functional, and treatment characteristics of patients with EPS and long-term PD controls

Characteristic	Patients with EPS (n=7)	Controls (n=28)	P Value
Men	71	71	1.00
PD duration, mo	57.8±7.6	55.9±4.2	0.84
Age at PD start, yr	47.5±3.6	56.9±3.4	0.09
Underlying nephropathy			0.24
GN	43	32
Vascular nephropathy	14	21
Chronic pyelonephritis	0	21
Genetic disease	14	21
Other or undetermined	29	4
Charlson comorbidity index	4.9±1.0	4.6±0.4	0.85
Diabetes, n	2	4	0.17
Residual diuresis, ml/d	1083±159	1021±130	0.78
Body mass index, kg/m2	22.9±1.1	22.3±0.6	0.67
Medications
ACE inhibitors and/or ARBs	57	63	0.78
Statins	43	29	0.10
β-blockers	29	14	0.58
Baseline adequacy
Peritoneal Kt/V	1.51±0.22	1.46±0.07	0.84
Residual Kt/V	0.97±0.16	0.80±0.09	0.42
Total Kt/V	2.48±0.15	2.23±0.09	0.20
Baseline functional parameters
Net UF, ml	743±124	648±57	0.54
D/P creatinine, 4 h	0.75±0.05	0.74±0.05	0.96
Sodium sieving	0.05±0.01	0.05±0.01	0.44
PD modality, % APD	100	68	0.11
Glucose and icodextrin exposure
Mean annual glucose exposure, kg	122±9	110±7	0.20
Mean annual icodextrin exposure, kg	51±4	47±3	0.43
Peritonitis
Patients with peritonitis	71	71	1.00
No. of peritonitis per patient	1.4±0.4	1.3±0.2	0.84
Peritonitis rate, patient−1×year−1	0.36±0.11	0.30±0.05	0.66
Patients with GNR peritonitis	14	43	0.12

Data are presented as the mean±SEM or percentage, unless otherwise indicated. ACE, angiotensin converting enzyme; ARB, angiotensin 2 receptor antagonist; D/P, dialysate-over-plasma; APD, automated peritoneal dialysis; GNR, Gram-negative rod.